Evidence map›Paper›PMID 33627737›Full record

ArticleScientific reports2021

Poly(p-phenylenevinylene) nanoparticles modified with antiEGFRvIII for specific glioblastoma therapy.

Yuchao Liang, Zelin Li, Huanxiang Yuan, Lei Wang, Li-Hua Gao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Nanotherapy of Glioblastoma-Where Hope Grows.International journal of molecular sciences · 2025
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Yuchao LiangNeurosurgery Department, Beijing Tian Tan Hospital, Capital Medical University, Beijing, 100070, People's Republic of China.
Zelin LiDepartment of Chemistry, College of Chemistry and Materials Engineering, Beijing Technology and Business University, Beijing, 100048, People's Republic of China.
Huanxiang YuanDepartment of Chemistry, College of Chemistry and Materials Engineering, Beijing Technology and Business University, Beijing, 100048, People's Republic of China. yhx@iccas.ac.cn.
Lei WangNeurosurgery Department, Beijing Tian Tan Hospital, Capital Medical University, Beijing, 100070, People's Republic of China. wanglei_tiantan@163.com.
Li-Hua GaoDepartment of Chemistry, College of Chemistry and Materials Engineering, Beijing Technology and Business University, Beijing, 100048, People's Republic of China. gaolh@th.btbu.edu.cn.
Beijing Technology and Business University · CNCapital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma is the most common primary brain cancer and it is nearly impossible to remove the entire tumor with surgery or a single drug. EGFRvIII is the most frequent genetic change associated with glioblastoma, so EGFRvIII-based targeting therapies provide promise for treating glioblastoma. Herein, poly[2-methoxy-5-(2'-ethylhexyloxy)-p-phenylenevinylene] (PPV) was used as the core to prepare a conjugated polymer nanoparticle (PPVN) modified with anti-EGFRvIII (PPVN-A) that exhibited high ROS generation ability under white light irradiation. PPVN-A could target EGFRvIII-overexpressed tumor cells and damaged more than 90% of tumor cells with the light illumination while PPVN without modification exhibited no obvious cytotoxicity toward these cells under the same condition. Thus, the photodynamic treatment of glioblastoma cells using PPVN-A could be achieved, indicating the potential of anti-EGFRvIII-modified nanoparticles as a therapeutic material for treating glioblastoma in clinic.

Indexed as

Brain NeoplasmsCell LineCell Line, TumorErbB ReceptorsGlioblastomaHEK293 CellsHumansNanoparticlesPolymersPolyvinylsepidermal growth factor receptor VIIIErbB Receptorspoly(4-phenylenevinylene)PolymersPolyvinyls

Identifiers

PMID33627737
PMCPMC7904835
OpenAlexW3131327682

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.